Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis

References

• Ju Q, Li XM, Zhang H, et al. BRCA1-associated Protein is a potential prognostic biomarker and is correlated with immune infiltration in liver hepatocellular carcinoma: a pan-cancer analysis. Front Mol Biosci. 2020;7:573619.
   PubMed Web of Science ®Google Scholar
• Cable J, Greenbaum B, Pe’er D, et al. Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci. 2021;1489(1):30–47.
   PubMed Web of Science ®Google Scholar
• Xing C, Sun SG, Yue ZQ, et al. Role of lncRNA LUCAT1 in cancer. Biomed Pharmacothe. 2021;134:111158.
   PubMed Web of Science ®Google Scholar
• Guo X, Gao L, Liao Q, et al. Long non-coding RNAs function annotation: a global prediction method based on bi-colored networks. Nucleic Acids Res. 2013;41(2):e35.
   PubMed Web of Science ®Google Scholar
• Peng L, Chen Y, Ou Q, et al. LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma. Int Immunopharmacol. 2020;89(Pt A):107071.
   PubMed Web of Science ®Google Scholar
• Xu S, Wang Q, Kang Y, et al. Long noncoding RNAs control the modulation of immune checkpoint molecules in cancer. Cancer Immunol Res. 2020;8(7):937–951.
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang N, Song P, et al. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020;53(9):e12855.
   PubMed Web of Science ®Google Scholar
• Xu M, Xu X, Pan B, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer. 2019;18(1):135.
   PubMed Web of Science ®Google Scholar
• Hoadley KA, Yau C, Wolf DM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929–944.
   PubMed Web of Science ®Google Scholar
• Fu T, Ji K, Jin L, et al. ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer. Gastric Cancer. 2021;24(1):45–59.
   PubMed Web of Science ®Google Scholar
• Tan LJ, Liu JT, Yang M, et al. LncRNA ASB16-AS1 promotes proliferation and inhibits apoptosis of non small cell lung cancer cells by activating the Wnt/β catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(4):1870–1876.
   PubMed Web of Science ®Google Scholar
• Yin R, Liu J, Zhao D, et al. Long non-coding RNA ASB16-AS1 functions as a miR-760 sponge to facilitate the malignant phenotype of osteosarcoma by increasing HDGF expression. Onco Targets Ther. 2020;13:2261–2274.
   PubMed Web of Science ®Google Scholar
• Ren FH, Yang H, He RQ, et al. Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma. BMC Cancer. 2018;18(1):12.
   PubMedGoogle Scholar
• Jia D, Li S, Li D, et al. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging (Albany NY). 2018;10(4):592–605.
   PubMedGoogle Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–w514.
   PubMed Web of Science ®Google Scholar
• Huemer F, Leisch M, Geisberger R, et al. Combination strategies for immune-checkpoint blockade and response prediction by artificial intelligence. Int J Mol Sci. 2020;21(8). DOI:10.3390/ijms21082856.
   PubMed Web of Science ®Google Scholar
• Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121(10):809–818.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zheng Y, Li X, et al. Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma. Ann Transl Med. 2019;7(18):427.
   PubMed Web of Science ®Google Scholar
• Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2019;51(2):411–412.
   PubMed Web of Science ®Google Scholar
• Liu YC, Lin P, Zhao YJ, et al. Pan-cancer analysis of clinical significance and associated molecular features of glycolysis. Bioengineered. 2021;12(1):4233–4246.
   PubMed Web of Science ®Google Scholar
• Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321–337. e310.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981.
   PubMed Web of Science ®Google Scholar
• Meng XH, Chen XD, Greenbaum J, et al. Integration of summary data from GWAS and eQTL studies identified novel causal BMD genes with functional predictions. Bone. 2018;113:41–48.
   PubMed Web of Science ®Google Scholar
• Tan LJ, Liu JT, Yang M, et al. LncRNA ASB16-AS1 promotes proliferation and inhibits apoptosis of non small cell lung cancer cells by activating the Wnt/β catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2021;25(4):1766.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhou H, Liu J, et al. Long noncoding RNA ASB16-AS1 promotes proliferation, migration, and invasion in glioma cells. Biomed Res Int. 2019;2019:5437531.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhuang R, Feng S, et al. Long non-coding RNA ASB16-AS1 enhances cell proliferation, migration and invasion via functioning as a ceRNA through miR-1305/Wnt/β-catenin axis in cervical cancer. Biomed Pharmacothe. 2020;125:109965.
   PubMed Web of Science ®Google Scholar
• Chen YG, Satpathy AT, Chang HY., et al. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 2017;18(9):962–972.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang L, Xu Y, et al. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. J Cell Physiol. 2020;235(12):9304–9316.
   PubMed Web of Science ®Google Scholar
• Shen Y, Peng X, Shen C., et al. Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 2020;112(3):2640–2646.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35.
   PubMed Web of Science ®Google Scholar
• Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–354.
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093–1102.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu Y, Dai X, et al. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma. Exp Eye Res. 2020;196:108069.
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Ivan C, Amero P, et al. Explainable artificial intelligence reveals novel insight into tumor microenvironment conditions linked with better prognosis in patients with breast cancer. Cancers (Basel). 2021;13(14). DOI:10.3390/cancers13143450.
   Web of Science ®Google Scholar
• Toor SM, Murshed K, Al-Dhaheri M, et al. Immune checkpoints in circulating and tumor-infiltrating CD4(+) T Cell subsets in colorectal cancer patients. Front Immunol. 2019;10:2936.
   PubMed Web of Science ®Google Scholar
• Mami-Chouaib F, Blanc C, Corgnac S, et al. Resident memory T cells, critical components in tumor immunology. J Immunother Cancer. 2018;6(1):87.
   PubMedGoogle Scholar
• Rana J, Biswas M. Regulatory T cell therapy: current and future design perspectives. Cell Immunol. 2020;356:104193.
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25–39.
   PubMed Web of Science ®Google Scholar
• Tixier F, Cheze-le-rest C, Schick U, et al. Transcriptomics in cancer revealed by positron emission tomography radiomics. Sci Rep. 2020;10(1):5660.
   PubMed Web of Science ®Google Scholar